Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -77.23% is 37% above its 4-year average of -122.46%, near the high end of its 4-year range (-343.85%–-17.11%).
As of the fiscal period ended Tuesday, June 30, 2026. 42.35% above its 12-month average of -133.95%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -77.23%.
RETURN ON EQUITY (ROE)
-77.23%
RETURN ON EQUITY (ROE) AVG TTM
-133.95%
RETURN ON EQUITY (ROE) AVG 3Y
-143.74%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+42.35%
CURRENT VS 3Y AVG
+46.27%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-36.00%
median of 392 covered companies
CURRENT VS SECTOR MEDIAN
-114.49%
vs the sector median at left
Bluejay Diagnostics, Inc.
Market Cap
$787624.00
Return on Equity (ROE)
-77.23%
TTM Avg
-133.95%
3Y Avg
-143.74%
5Y Avg
N/A
Market Cap
$707297.00
Return on Equity (ROE)
6.58%
TTM Avg
129.48%
3Y Avg
106.12%
5Y Avg
-3462.32%
Market Cap
$878396.00
Return on Equity (ROE)
-73.66%
TTM Avg
-87.93%
3Y Avg
-127.18%
5Y Avg
-86.65%
Market Cap
$885939.00
Return on Equity (ROE)
N/A
TTM Avg
-255.88%
3Y Avg
-273.58%
5Y Avg
-200.54%
Market Cap
$888387.00
Return on Equity (ROE)
-334.41%
TTM Avg
-290.71%
3Y Avg
-280.75%
5Y Avg
-198.19%
Market Cap
$570131.00
Return on Equity (ROE)
-66.26%
TTM Avg
77.79%
3Y Avg
-17.48%
5Y Avg
-22.53%
Market Cap
$1.02M
Return on Equity (ROE)
-93.97%
TTM Avg
234.49%
3Y Avg
123.23%
5Y Avg
1171.22%
Market Cap
$1.11M
Return on Equity (ROE)
-57.87%
TTM Avg
-222.45%
3Y Avg
-164.72%
5Y Avg
-135.78%
Market Cap
$1.14M
Return on Equity (ROE)
-11.85%
TTM Avg
-6.20%
3Y Avg
47.36%
5Y Avg
47.36%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bluejay Diagnostics, Inc. (BJDX) | $787624.00 | -77.23% | -133.95% | -143.74% | N/A |
| CDT Equity Inc. (CDT)vs › | $707297.00 | 6.58% | 129.48% | 106.12% | -3462.32% |
| Bone Biologics Corporation (BBLG)vs › | $878396.00 | -73.66% | -87.93% | -127.18% | -86.65% |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | N/A | -255.88% | -273.58% | -200.54% |
| Decoy Therapeutics Inc. (DCOY)vs › | $888387.00 | -334.41% | -290.71% | -280.75% | -198.19% |
| HCW Biologics Inc. (HCWB)vs › | $570131.00 | -66.26% | 77.79% | -17.48% | -22.53% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | -93.97% | 234.49% | 123.23% | 1171.22% |
| Clearmind Medicine Inc. (CMND)vs › | $1.11M | -57.87% | -222.45% | -164.72% | -135.78% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.14M | -11.85% | -6.20% | 47.36% | 47.36% |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | N/A | 558.67% | 54.46% | -8.27% |
ROE
-77.2%
ROA
-63.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -77.23% |
| 2026-03-31 | -165.10% |
| 2025-12-31 | -114.61% |
| 2025-09-30 | -185.51% |
| 2025-06-30 | -127.31% |
| 2025-03-31 | -187.61% |
| 2024-12-31 | -134.70% |
| 2024-09-30 | -119.88% |
| 2024-06-30 | -108.84% |
| 2024-03-31 | -289.33% |
| 2023-12-31 | -343.85% |
| 2023-09-30 | -192.54% |
| 2023-06-30 | -167.80% |
| 2023-03-31 | -107.20% |
| 2022-12-31 | -80.55% |
| 2022-09-30 | -60.61% |
| 2022-06-30 | -39.65% |
| 2022-03-31 | -28.71% |
| 2021-12-31 | -17.11% |
